Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 161 to 170 of 220 total matches.
Gallium For Hypercalcemia of Malignancy
The Medical Letter on Drugs and Therapeutics • May 03, 1991 (Issue 843)
of gallium Cost gallium for hypercalcemia Cancer chemotherapy calcitonin Calcimar furosemide Gallium ...
Gallium nitrate (Ganite - Fujisawa, USA), originally an anticancer drug, was recently marketed for treatment of cancer-associated hypercalcemia that has not responded to hydration. Other drugs used for treatment of hypercalcemia include furosemide (Lasix, and others), the bisphosphonate etidronate (Didronel IV), calcitonin (Calcimar), and plicamycin (Mithracin, formerly mithramycin) (RAB Schaiff et al, Clin Pharm, 8:108, 1989). Newer bisphosphonates are available in Europe.
Fludarabine
The Medical Letter on Drugs and Therapeutics • Sep 20, 1991 (Issue 853)
for CLL Cancer chemotherapy Chlorambucil Fludara Fludarabine for leukemia leukemia chronic lymphocytic ...
Fludarabine phosphate (Fludara - Berlex), an analog of vidarabine (Vira-A), was recently approved by the U.S. Food and Drug Administration for treatment of patients with refractory chronic lymphocytic leukemia (CLL). The drug has not yet been marketed but is still available, as it has been for two years, through the National Cancer Institute.
Anastrozole for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jul 05, 1996 (Issue 978)
response usually receive systemic chemotherapy (Medical Letter, 37:25, 1995).
PHARMACOKINETICS ...
Anastrozole (Arimidex - Zeneca), a selective nonsteroidal aromatase inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen (Nolvadex, and others).
Samarium-153 Lexidronam for Painful Bone Metastases
The Medical Letter on Drugs and Therapeutics • Aug 29, 1997 (Issue 1008)
for CANCER CHEMOTHERAPY samarium-153 lexidronam for bone metastases Cost of samarium-153 lexidronam Metastron ...
Samarium-153 lexidronam (Quadramet - Dupont Pharma) has been approved by the FDA for relief of pain in patients with osteoblastic bone metastases. Strontium-89 (Metastron) has been available for several years for this indication (Medical Letter, 35:102, 1993).
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
The Medical Letter on Drugs and Therapeutics • Jan 09, 2012 (Issue 1381)
is the
first-line therapy; various chemotherapy regimens
including doxorubicin, dacarbazine and 5-fluorouracil ...
The FDA recently approved vandetanib [van det´ a nib]
(Caprelsa – AstraZeneca) for oral treatment of symptomatic
or progressive medullary thyroid cancer (MTC) in
patients with unresectable locally advanced or metastatic
disease. Vandetanib is the first drug approved in the
US for medullary thyroid cancer.
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use ...
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type human
epidermal growth factor receptor 2 (HER2)-positive
unresectable or metastatic colorectal cancer
that has progressed following treatment with
fluoropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use in combination with trastuzumab and
capecitabine (Xeloda, and generics) for treatment
of adults with advanced unresectable or...
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e37-8 doi:10.58347/tml.2023.1670g | Show Introduction Hide Introduction
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
or refractory DLBCL is generally
aggressive salvage chemotherapy or autologous
stem-cell transplantation ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Sotorasib (Lumakras) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
. Sotorasib is the
first KRAS inhibitor to be approved in the US.
chemotherapy and a programmed death 1 (PD ...
Sotorasib (Lumakras — Amgen), an oral KRAS
inhibitor, has received accelerated approval by the
FDA for treatment of KRAS G12C-mutated locally
advanced or metastatic non-small cell lung cancer
(NSCLC) in adults who received at least one prior
systemic therapy. Accelerated approval was based
on the overall response rate and duration of response.
KRAS mutations are found in 25-30% of non-squamous-cell NSCLC cases and the G12C mutation
is the most common KRAS mutation. Sotorasib is the
first KRAS inhibitor to be approved in the US.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e104-5 doi:10.58347/tml.2023.1678e | Show Introduction Hide Introduction
Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
within
the previous 1-5 years. Patients previously treated
with chemotherapy or radiation were excluded ...
The FDA has approved vorasidenib (Voranigo –
Servier), an oral isocitrate dehydrogenase (IDH)
inhibitor, for treatment of grade 2 astrocytoma or
oligodendroglioma in patients ≥12 years old with
an IDH1 or IDH2 mutation. It is the first systemic
treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e188-9 doi:10.58347/tml.2024.1715g | Show Introduction Hide Introduction
In Brief: A New Non-Small Cell Lung Cancer Indication for Osimertinib (Tagrisso) (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
in combination with pemetrexed and platinum-
based chemotherapy for locally advanced or metastatic
NSCLC ...
The oral kinase inhibitor osimertinib (Tagrisso –
AstraZeneca), which has been available for years for
treatment of non-small cell lung cancer (NSCLC) in
adults with epidermal growth factor receptor (EGFR)
exon 19 deletions or exon 21 L858R mutations, has now
been approved for treatment of unresectable stage III
EGFR-mutated NSCLC. About 20-30% of patients with
NSCLC have locally advanced stage III NSCLC, and
60-90% of these patients have unresectable disease.
Osimertinib is the first targeted therapy to be approved
for the new indication.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e190-1 doi:10.58347/tml.2024.1715h | Show Introduction Hide Introduction